Background: Microglia, the brain's principal immune cell, are increasingly implicated in Alzheimer's disease (AD), but the molecular interfaces through which these cells contribute to amyloid beta (Aβ)-related neurodegeneration are unclear. We recently identified microglial contributions to the homeostatic and disease-associated modulation of perineuronal nets (PNNs), extracellular matrix structures that enwrap and stabilize neuronal synapses, but whether PNNs are altered in AD remains controversial.
The use of advanced technological solutions (“neurotechnologies”) can improve the clinical outcomes of neurorehabilitation after stroke. Here, Micera et al. propose a paradigm shift that is based on a deep understanding of the basic mechanisms of natural stroke recovery and technology-assisted neurorehabilitation to improve the clinical effectiveness of neurotechnology.
Perinatal depression (PND) is a heterogeneous disorder with differences in timing of onset of depression, which influences symptomology, severity, and treatment efficacy. Researchers must embrace the heterogeneity to bring fruition to a precision medicine approach for women in reproductive mental health care. Galea and Frokjaer discuss the heterogeneity of perinatal depression based on timing onset, which influences symptoms and has implications for etiology and treatment efficacy. The clinical and research community can exploit this heterogeneity to uncover precision treatment strategies.
